ALLR

Allarity Therapeutics, Inc. (ALLR) - 10-Q Summary

Business Context and Reporting Period

Allarity Therapeutics, Inc. is a clinical-stage precision medicine pharmaceutical company focused on developing anti-cancer therapeutics, primarily its lead candidate stenoparib, utilizing its proprietary Drug Response Predictor (DRP®) platform. This report covers the quarterly period ended June 30, 2025. The Company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company. As of August 14, 2025, there were 14,619,636 shares of common stock outstanding.

Key Financial Metrics

Note: The Company has no revenue. Operating expenses consist of Research and Development ($3.7M) and General and Administrative ($3.4M) for the six-month period.

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses decreased by $0.4 million compared to the prior six-month period. This was driven by a $0.9 million decrease in General and Administrative expenses (due to reduced professional services), partially offset by a $0.5 million increase in Research and Development expenses (driven by the expansion of the Phase II clinical trial for stenoparib).
• Other Income: Net other income remained relatively flat at $2.1 million. However, the composition shifted significantly. The 2024 period included a $2.7 million gain from the change in fair value of derivative liabilities, whereas the 2025 period included a $1.7 million foreign exchange gain.
• Financing Activities: Net cash provided by financing activities dropped significantly from $27.7 million in 2024 to $8.6 million in 2025. This reflects the termination of the At-The-Market (ATM) offering in March 2025 and the initiation of a share repurchase program, which utilized $2.6 million in cash.
• Liabilities: Accrued expenses decreased by $2.3 million, largely due to the payment of a $2.5 million SEC settlement penalty in April 2025.

Guidance, Outlook, and Risks

• Liquidity: Management estimates that existing cash of $17.8 million is sufficient to fund operations for at least the next 12 months. The Company expects to incur significant expenses to advance stenoparib through clinical trials and regulatory approval.
• SEC Settlement: The Company settled an SEC investigation regarding disclosures related to its Dovitinib NDA. A one-time civil penalty of $2.5 million was paid in April 2025.
• Internal Controls: The Company identified a material weakness in internal control over financial reporting related to the accounting of the share repurchase plan initiated in Q2 2025. Management is implementing remediation plans, including updated policies and enhanced review processes.
• Leadership Changes: Alexander Epshinsky resigned as CFO effective June 30, 2025, and was replaced by Jeffrey S. Ervin on July 1, 2025. Joseph W. Vazzano resigned as a director, replaced by Jesper Høiland.
• Novartis Liability: Following the termination of a license agreement with Novartis in January 2024, the Company has a current liability of approximately $5.4 million (comprising accounts payable, convertible notes, and accrued liabilities) related to the agreement.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $17.8 million cash balance against the projected burn rate for the stenoparib Phase II trial expansion.
• Internal Control Remediation: Monitor the progress of remediation for the material weakness in internal controls regarding share repurchase accounting.
• Novartis Obligations: Confirm the status and payment schedule of the $5.4 million liability owed to Novartis following the license termination.
• Capital Raising: Assess the Company's ability to raise additional capital given the termination of the ATM facility and the need to fund future clinical trials.
• Share Repurchase Impact: Evaluate the impact of the $2.6 million share repurchase on liquidity and the remaining $2.4 million authorization under the program.